Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFM) Net Income towards Common Stockholders: 2012-2024

Historic Net Income towards Common Stockholders for Sunshine Biopharma (SBFM) over the last 11 years, with Dec 2024 value amounting to -$5.1 million.

  • Sunshine Biopharma's Net Income towards Common Stockholders rose 124.71% to $295,951 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.0 million, marking a year-over-year decrease of 8.76%. This contributed to the annual value of -$5.1 million for FY2024, which is 13.94% down from last year.
  • Latest data reveals that Sunshine Biopharma reported Net Income towards Common Stockholders of -$5.1 million as of FY2024, which was down 13.94% from -$4.5 million recorded in FY2023.
  • Sunshine Biopharma's Net Income towards Common Stockholders' 5-year high stood at -$2.8 million during FY2020, with a 5-year trough of -$26.7 million in FY2022.
  • Over the past 3 years, Sunshine Biopharma's median Net Income towards Common Stockholders value was -$5.1 million (recorded in 2024), while the average stood at -$12.1 million.
  • As far as peak fluctuations go, Sunshine Biopharma's Net Income towards Common Stockholders plummeted by 346.70% in 2021, and later spiked by 83.15% in 2023.
  • Over the past 5 years, Sunshine Biopharma's Net Income towards Common Stockholders (Yearly) stood at -$2.8 million in 2020, then tumbled by 346.70% to -$12.4 million in 2021, then crashed by 115.05% to -$26.7 million in 2022, then skyrocketed by 83.15% to -$4.5 million in 2023, then declined by 13.94% to -$5.1 million in 2024.